Prestige Consumer Healthcare (PBH) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prestige Consumer Healthcare (PBH) has outperformed Arcus Biosciences (RCUS) over the past year, losing 16.5% versus a loss of 29.2%. Over five years, PBH leads with a -12.0% price change compared with -66.3% for RCUS. Prestige Consumer Healthcare is the larger company by market cap ($2.35 billion vs $2.25 billion), about 1.0 times the size, while Arcus Biosciences is growing revenue faster (-4.3% vs -4.3%).
Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -142.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBH | RCUS |
|---|---|---|
| Share price | $49.63 | $15.62 |
| Market cap | $2.35B | $2.25B |
| 1-day change | +0.06% | -1.01% |
| YTD return | -19.55% | -34.45% |
| 1-year return | -16.48% | -29.16% |
| 5-year return | -12.02% | -66.31% |
| P/E ratio (TTM) | 15.32 | — |
| Forward P/E | 9.76 | — |
| EPS (TTM) | $3.24 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.09B | $247.00M |
| Revenue growth (YoY) | -4.31% | -4.26% |
| Net income (latest FY) | $190.30M | $-353.00M |
| Gross margin | 54.71% | — |
| Operating margin | 28.42% | -156.28% |
| Net margin | 17.48% | -142.91% |
| 52-week high | $71.07 | $31.74 |
| 52-week low | $41.77 | $15.56 |
| Distance from 52-week high | -30.17% | -50.78% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +33.39% | +162.48% |
| Average volume | 583.25K | 1.85M |
| Shares outstanding | 47.40M | 143.99M |
| Employees | 890 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBH has outperformed RCUS by 12.7 percentage points over the past year.
- Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
PBH vs RCUS FAQ
Which is bigger, Prestige Consumer Healthcare or Arcus Biosciences?
Prestige Consumer Healthcare (PBH) is larger, with a market capitalization of $2.35B compared with $2.25B for Arcus Biosciences (RCUS).
Which stock has performed better over the past year, PBH or RCUS?
PBH returned -16.48% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Prestige Consumer Healthcare and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.